Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Rhea-AI Summary

Nyxoah SA has announced the release of its financial results for the fourth quarter and full year 2022 on March 22, 2023, after market close. The company will host a conference call to discuss the results starting at 10:30pm CET / 4:30pm ET. Nyxoah is focused on developing solutions for Obstructive Sleep Apnea (OSA), with its lead product, the Genio® system, holding a CE Mark since 2019. The product aims to offer innovative treatment for patients with OSA, having received CE approval for expanding its indications.

Positive

• Successful completion of the BLAST OSA study.
• Genio® system received European CE Mark in 2019.
• Positive outcomes from the BETTER SLEEP study expanded therapeutic indications.
• Ongoing DREAM IDE pivotal study for FDA approval.

Negative

• None.

Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Mont-Saint-Guibert, Belgium – March 8, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and full year 2022 on Wednesday, March 22, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

Investors interested in listening to the conference call may do so by registering for a unique personal PIN at the following link:  Conference Registration (vevent.com). A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.nyxoah.com/events.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

• ENGLISH_Q4 2022 Earnings Call Save-the-Date

FAQ

What date will Nyxoah release its financial results?

Nyxoah will release its financial results on March 22, 2023.

What is Nyxoah's main product for treating sleep apnea?

Nyxoah's main product is the Genio® system, designed for treating Obstructive Sleep Apnea.

What is the significance of the CE Mark for Nyxoah?

The CE Mark allows Nyxoah to sell the Genio® system in Europe, confirming its compliance with safety standards.

When will the conference call regarding the financial results take place?

The conference call will take place on March 22, 2023, at 10:30pm CET / 4:30pm ET.